PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 96.4% from PeptideMeter with 98.8% from the supplier?

Asked 30 Apr 2024Modified 2.0 years agoViewed 63k times
35

The particulars: 96.4% · PeptideMeter · 98.8%.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What is the most likely explanation, and how would I confirm it?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
SI
askedsample_id17k2730 Apr 2024
3The arithmetic checks out. I ran the same numbers and got the same result. – Dr_Wren_Halliday 6 months ago
add a comment

2 Answers

Accepted answer first, then by votes
105

Accepted answer

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
SC
answered · acceptedstopper_core50k13817 Jun 2024
7I would gently push back on the second point — the evidence there is thinner than stated. – eoin_mcgarry 3 months ago
6Adding for future readers: the certificate should carry the lot number, not just a batch code. – deamidation_watch 40 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
91

Start from what the detector sees, because that tells you what the number means.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Worth being precise here: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 19 Jul 2024 by juliette_farnese — corrected a unit error in the worked example

shareimprove this answerflag
JF
answeredjuliette_farnese12k2828 Jun 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.